BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

Bristol Myers Squibb (BMY) announced that it has obtained a positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency for two of its drugs.The CHMP recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).The CHMP also recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for relapsed or refractory follicular lymphoma. ...